• Svenska

Oasmia logoOasmia logo

  • About Oasmia
    • Our Company
    • Vision and mission
    • History
    • Corporate Governance
      Articles of Association
      General Meeting
      Board of Directors
      Nomination Committee
      Management
      Auditor
      Code of Business Conduct and Ethics
  • Our technology and portfolio
    • Our technology
    • Our product portfolio
    • Production
    • Research and development
  • Key therapeutic areas
    • Market Human Health
    • Market Animal Health
  • Investors
    • The Share
      Ownership Structure
    • Financial Reports and Presentations
      Prospectus
      SEC Filings
      Info regarding delisting of ADS from NASDAQ US
    • Press Releases
      Financial calendar
    • Subscribe
      Contacts
  • News and events
    • Press releases
    • Subscribe
    • Events
    • Contacts
  • Career
    • Vacant positions
    • Contacts
  • Contacts
    • Offices
    • About Oasmia
      • Our Company
      • Vision and mission
      • History
      • Corporate Governance
      • Articles of Association
      • General Meeting
      • Board of Directors
      • Nomination Committee
      • Management
      • Auditor
      • Code of Business Conduct and Ethics
    • Our technology and portfolio
      • Our technology
      • Our product portfolio
      • Production
      • Research and development
    • Key therapeutic areas
      • The market for Human Health
      • The market for Animal Health
    • Investors
      • The Share
      • Ownership Structure
      • Financial Reports and Presentations
      • Prospectus
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
      • Press releases
      • Financial calendar
      • Subscribe
      • Contacts
    • News and events
      • Press releases
      • Subscribe
      • Events
      • Contacts
    • Career
      • Vacant positions
      • Contacts
    • Contacts
      • Offices
    • Svenska
    March 19, 2019

    Extraordinary General Meeting 2019

    Extraordinary General Meeting was held on March 19, 2019 in Oasmias offices in Uppsala.

    The documentation from the Meeting is available in PDF format below.

    Documents

    • Minutes
      Swedish 19 March, 2019
    • Notice
      English 5 Febuary, 2019
    • Proxy
      English 2019
    oasmia2017-0567

    Our Company

    At Oasmia Pharmaceutical AB we are developers of a new generation of drugs within the fields of human and veterinary oncology.

    Read more

    The Share

    Follow the share

    Share this page

    Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR17.

    Oasmia Pharmaceutical AB

    Vallongatan 1, 752 28 Uppsala, Sweden
    Tel +46 18 50 54 40
    Fax +46 18 51 08 73
    info@oasmia.com

    • Personal data
    • Cookies

    We uses cookies in order to optimize your use of our website. Read more about cookies.

    OK